Navigation Links
Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program
Date:10/14/2009

>

Excellarate Product Candidate

The Excellarate product candidate is initially being developed to facilitate wound closure in non-healing diabetic foot ulcers. Excellarate is a collagen-based topical gel employing Cardium's Gene Activated Matrix(TM) technology to locally stimulate the release of platelet-derived growth factor-B protein (PDGF-B) and provide a matrix for cell migration, which are believed to be important keys in the human body's wound healing process. The sustained localized release and retention of PDGF-B by a patient's own cells directly at the wound site is believed to stimulate angiogenesis and granulation tissue formation through the recruitment and proliferation of cells such as monocytes, fibroblasts and endothelial cells. These cell types are considered critical for the effective stimulation of a variety of wound healing processes.

The Excellarate product candidate is being designed to provide physicians and patients with a potentially simpler, easy-to-use treatment regimen compared to most diabetic wound healing agents or devices in use that require repeated administrations over a long term (weeks to months). Based on recently announced advancements, Excellarate is also expected be re-formulated as an easy-to-use single syringe that would be pre-mixed and ready to be applied to patients' wounds. The reformulation will allow Excellarate to be maintained in a physician's office using a standard refrigerator (at a temperature of about 4 degrees C) and is expected to have a shelf life of at least 15-18 months.

Gene Activated Matrix Technology Platform

Cardium's proprietary Gene Activated Matrix(TM) technology platform is designed to provide a therapeutic level of protein synthesis at a specific site in the body and can be used in soft tissue such as skin, ligament, tendons and cartilage, as well as in hard tissue such as bone. The technology is distinctive in that it is immobilized gene del
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers
2. Scientific Journal Gene Therapy Reports That Cardiums Gene Activated Matrix Technology Accelerates Periodontal Tissue Regeneration
3. Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments
4. Cardium Completes Sale of InnerCool Therapies Business to Royal Philips Electronics
5. Cardium Receives Preliminary Notification of Inclusion in the Russell 3000(R) Index and Russell Global(R) Index
6. Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
7. Cardium Reports on First Quarter 2009 Financial Results and Recent Developments
8. Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications
9. Cardium Provides Update Regarding Exchange Listing Compliance Plan Accepted by NYSE Amex
10. Cardiums InnerCool Announces Journal of Neurotrauma Highlights Hypothermia Therapys Role in Post Cardiac Arrest, and Traumatic Brain and Spinal Cord Injury Patients
11. Cardium Reports on Recent Highlights, Financial Results and 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 Doctors at the ... to wipe out mesothelioma in laboratory mice by injecting them ... just posted details of the study on its website. ... Scientists with Hong Kong University’s AIDS Institute of Microbiology created ... 1” or PD-1. By altering DNA, the vaccine is designed ...
(Date:8/20/2014)... City, New Jersey (PRWEB) August 20, 2014 ... in meeting the needs of an estimated tens of ... introduction of the new Bill A3525—a bill that would ... patients to grow their own cannabis—earlier this summer by ... horticultural training for medicinal quality marijuana is growing. , ...
(Date:8/20/2014)... August is Children’s Eye Health and Safety ... eye health and safety for their children and have ... that must be checked for, according to Sharon Kleyne, ... radio show, is pediatric dry eye. With computer use ... is becoming a very real concern to ophthalmologists. , ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Hope For ... Give Hope® Celebration to be hosted in Washington, DC ... Navy Club. This signature event honors the courage of ... of the fallen. Proceeds from the Got Heart, Give ... national nonprofit dedicated to restoring a sense of self, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Building ... healthcare, Jvion successfully predicted stage iii and iv ... in some situations, approached 90%. A company spokesperson ... achieved in commercial or academic settings. The resulting ... all types of hospital-acquired conditions to help providers ...
Breaking Medicine News(10 mins):Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2
... The findings might boost understanding of the disease generally, ... The adult children of people with the rarer, inherited ... new study to better understand the biology of the ... biological parent diagnosed with a known genetic mutation causing ...
... 28 /PRNewswire-Asia/ -- CCID Consulting, China,s leading,research, consulting and ... listed in Hong Kong (Hong Kong Stock Exchange:,HK08235), recently ... , In 2007, ... an increase,in health awareness, which in turn drove the ...
... MD, noted medical researcher and women,s health practitioner, has spoken out ... well as other oral bisphosphonates such as Boniva, Actonel, and Fosamax. ... ... Susan Lark, MD , noted medical researcher and women,s health ...
... Africa, Nov. 27 20 top international,and local companies ... Awards Banquet held tonight at the Michelangelo Hotel in ... and innovation,across a variety of sectors. , ... , The awards ...
... after its use was banned, statistics show that nearly 4,000 people in the ... , ... Manchester,UK (PRWEB) November 27, 2008 -- On 24th November 1999, the Government,s ... statistics show that nearly 4,000 people in the UK die each year from ...
... care nurses are considering quitting in the next year ... Melbourne study. , The study, conducted by the Centre ... and the Australian Nursing Federation finds Victoria,s registered nurses ... not committed to their workplace. , It cites excessive ...
Cached Medicine News:Health News:Study Recruiting From Alzheimer's-Prone Families 2Health News:CCID Consulting Discusses China's Medical Equipment Market 2Health News:CCID Consulting Discusses China's Medical Equipment Market 3Health News:CCID Consulting Discusses China's Medical Equipment Market 4Health News:CCID Consulting Discusses China's Medical Equipment Market 5Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 2Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 3Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 4Health News:Frost & Sullivan Recognises Best-in-Class Innovators 2Health News:Frost & Sullivan Recognises Best-in-Class Innovators 3Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 2Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 3Health News:Aged care workers to leave industry en masse due to stress, warns University of Melbourne study 2
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
(Date:8/19/2014)... Md. , Aug. 19, 2014  Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... offering announced last Thursday, August 14, 2014, has closed.  ... are convertible at $7.30 per share of common stock.  ... months, to purchase up to an additional 30% of ...
(Date:8/19/2014)... YORK , Aug. 19, 2014  As ... around the country, Bernstein Liebhard LLP notes that ... can choose between a number of options that ... dangerous surgical instrument. According to a report published ... th , these options include a mini-laparotomy and ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3
... 24 Children,s Mental Focus,Foundation (CMFF), a nonprofit ... that may be linked to children with autism ... currently working with,doctors that have patients afflicted with ... adults cope with behavioral problems,associated with mental disorders ...
... Marketers, who have the,primary responsibility for communicating the ... as top challenges for pharmaceutical,companies when communicating trial ... worry about competitors stealing your,thunder, but also worry ... According to a Best Practices, LLC benchmarking study, ...
Cached Medicine Technology:Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 2Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 3Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies 2
Inquire...
Inquire...
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... Fractionation, Proteins and Viruses • ... with fixed-angle rotor • Spin ... 85 mL • Operating temperature ... C • Rotors certified by ...
Medicine Products: